Viking Therapeutics (NASDAQ: VKTX) shares surged more than 80% premarket Monday after the company announced positive top-line results from its ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Hot List

Viking Therapeutic (VKTX) PT Raised to $80 at Stifel, '“Best-in-Class” Profile of Injectable VK2735 Stands Firm'February 27, 2024 12:06 PM Viking Therapeutic's (VKTX) Obesity Data Seen as 'Impressive'February 27, 2024 7:55 AM Novo Nordisk (NVO), Lilly (LLY) Decline Following Positive Data from Viking Therapeutics (VKTX)February 27, 2024 7:40 AM Form 8-K Viking Therapeutics, For: Feb 27February 27, 2024 7:05 AM Viking Therapeutics (VKTX) Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with ObesityFebruary 27, 2024 7:03 AM Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with ObesityFebruary 27, 2024 7:03 AM Ligand Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 7:00 AM